Regulatory T cells (Tregs) are specialized T cells with immunosuppressive functions and are expected to play a key role in the treatment of autoimmune and inflammatory diseases. To achieve such therapies, the use of artificially induced Tregs (iTregs) has attracted considerable attention as a means to overcome the limitations of naturally occurring Tregs (nTregs). However, challenges remain regarding the stability and functionality of these cells.

A research group led by Dr. Norihisa Mikami and Prof. Shimon Sakaguchi at the Immunology Frontier Research Center (WPI-IFReC), The University of Osaka, has developed a novel method to artificially induce Tregs using disease-causing T cells as the starting material.
(online publishing in Science Translational Medicine on Oct. 23, 2025 JST)

Contact

Sakaguchi Lab

shimonifrec.osaka-u.ac.jp

Experimental Immunology